Plain-English translation of NCT02792218 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple sclerosis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial examined how well ofatumumab—a new injectable medication given under the skin—worked compared to teriflunomide, an oral pill, in treating relapsing multiple sclerosis. About 900 people with relapsing MS received one of these two treatments over up to 2.5 years, and researchers tracked how often their relapses occurred and how safe each medication was.
Relapsing multiple sclerosis causes unpredictable flare-ups that can worsen disability over time. This study was designed to see whether this new injectable medication could reduce relapses and slow disease progression better than an existing oral treatment option.
Participants were randomly assigned to receive either the new injectable medication (given as injections under the skin every four weeks, with a loading phase at the start) plus placebo pills, or the oral medication taken daily plus placebo injections. Everyone received both injections and pills to keep them blinded to which treatment they were taking. Participants visited the clinic regularly for up to 2.5 years so researchers could monitor their relapses, disability, and any side effects.
AI-generated summary from trial data · Oct 11, 2026 · Not medical advice
United States